About TetraScience TetraScience is the Scientific Data and AI Company building Tetra OS, the operating system for scientific intelligence. We help the world’s leading life sciences firms turn fragmented scientific data into AI-native assets and scientific
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
General Information Job Advert Title: 【つくば】分析開発サイエンティスト・外部製造技術統括（SME） Location: Tokodai, Ibaraki Division: External Manufacturing Employment Class: Permanent Description Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies
General Information Job Advert Title: Senior Scientist（Biology PJ lead） Location: Tsukuba,Ibaraki Division: Cell and Gene Therapy Research Employment Class: Permanent Description 【About Astellas】 Astellas is a global life sciences company committed to turning innovative science into
General Information Job Advert Title: Senior Scientist, Applied Safety JP, Applied Safety Location: Tsukuba, Ibaraki Division: Early Development and Translational Science Employment Class: Permanent Description 【About Astellas】 Astellas is a global life sciences company committed to
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)